Therefore, TM4SF5 may be targeted using an anti-TM4SF5 reagent, such as a small compound TSAHC [25], or its antibody [19] as a potential NK cell-related immunotherapy for HCC, in addition to immunotherapies against PD-1, PD-L1, or CTLA-1 [12]. Here, GZMB is linked to hepatocellular carcinoma.